SecBot SecBot
144 ·Filed Sep 2, 2026

TARS

Tarsus Pharmaceuticals, Inc.
BEARISH
Impact 4/10
Horizondays Processed2mo ago SEC0001959173-26-006653
Form 144, notice of proposed sale of securities
Actionable Insight ▼ Bearish

Monitor for additional Form 144 or Form 4 filings by other insiders. The concentrated selling by a former officer over a short period could precede further insider exits or indicate a lack of conviction ahead of upcoming catalysts.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$82.76
T+0 close · Sep 2, 2026 · via day close
Latest settled
−5.01%
T+20 · $78.61 · next T+60 in 10d
Vs SPY
−4.68%
α at T+20
Latest observation
+3.64%
T+51 · FF3 residual α
  1. T+0 · Sep 2 $82.76entry
  2. T+1 · 3mo ago +0.54%α −0.51% · $83.21
  3. T+5 · 2mo ago −1.98%α −1.02% · $81.12
  4. T+20 · 7w ago −5.01%α −4.68% · $78.61
  5. T+52 · todayOpen
  6. T+60 · in 10d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Former officer Aziz Mottiwala filed a Form 144 to sell 8,000 shares (~$654k) of Tarsus Pharmaceuticals. This follows substantial recent sales of 212,073 shares (~$15.4M) over the prior two weeks. While the proposed sale is small relative to market cap, the pattern of aggressive selling by a former officer may signal reduced confidence.

Key Facts

  • Aziz Mottiwala (former officer) intends to sell 8,000 shares of common stock, estimated value $654,373.01.
  • Shares were acquired on 07/27/2020 via stock option exercise.
  • Mottiwala has already sold 53,043 shares on 08/19/2026, 81,332 shares on 08/25/2026, and 77,698 shares on 09/01/2026, totaling 212,073 shares (~$15.4M).
  • Proposed sale represents ~0.02% of TARS's $3.2B market cap; recent sales total ~0.48%.

Financial Impact

Proposed sale of $654k is small; recent aggregate sales of ~$15.4M are more material and may weigh on sentiment.

insider selling volumeshare price sentiment

Risk Factors

  • Further insider selling could pressure the stock.
  • The selling pattern may reflect negative private information about the company's outlook.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-006653
Document: 0001959173-26-006653-index.html0001959173-26-006653
Document: 0001959173-26-006653.txt0001959173-26-006653

Track record

21 reports on TARS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026